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It is often quoted that while short term graft survival in kidney transplantation has improved in recent 
years it has not translated into a commensurate improvement in long-term graft survival. We 
considered whether this were true of the entire experience of the national kidney transplant program in 
Ireland. A retrospective analysis of the National Kidney Transplant Service (NKTS) database was 
undertaken to investigate patient and graft survival for all adult first deceased donor kidney transplant 
recipients in Ireland, 1971-2015. 3260 recipients were included in this study. Kaplan-Meier methods 
were used to estimate survival at each time period post transplant for the various eras of 
transplantation. Uncensored graft survival has improved over the course of the program in Ireland at 
various time points despite risk factors for graft failure progressively increasing over successive eras. 
For example the graft survival at 15 years post transplant has increased from 10% in 1971-1975 to 
45% by 1996-2000. Ireland has experienced a progressive improvement in long term graft survival 
following kidney transplantation. Whether these trends are attributable to biological or non-biological 
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1. Introduction 
It is often reported that whilst short-term graft survival in kidney transplantation has improved 
in recent years it has not translated into a commensurate improvement in long term graft survival.[1-
4] This has been the case in the USA, in particular, but has also been reported in other jurisdictions.[5] 
We considered whether or not this was true of the National Kidney Transplant Service (NKTS) 
program in Ireland and set out to review the entire experience of our transplant program with over 
5,000 kidney transplants spanning 45 years.[6]  
The national kidney transplant program in Ireland has some attributes, which provide an 
interesting framework for the investigation of trends in allograft outcomes over time. This service has 
maintained a prospective kidney transplant registry with 98.9% complete follow up in terms of 
recipient outcome ascertainment. In addition, national healthcare policy in Ireland offers very 
affordable healthcare for recipients including contemporary immunosuppression medications and 
access to medical care [7, 8] This may not necessarily be the case in other jurisdictions within Europe 
or in the US.[9-14] Our objective in this study was to challenge the convention that long-term kidney 
allograft outcomes are failing to improve by assessing long term trajectories in Ireland.  
 
2. Materials and Methods 
 This was a retrospective analysis of the National Kidney Transplant Service (NKTS) Registry 
[15] to assess allograft and recipient outcomes. We analysed patient and graft survival for all adult 
(aged ≥ 18 years) first deceased donor kidney transplant recipients in Ireland. Of over 5,000 kidney 
transplants in the Irish program since its inception in 1964, 3,260 recipients were first adult deceased 
donor transplants during the period 1971–2015 and were included in this study. Complete data were 
available for 98.9% of these recipients included in this study. The NKTS Registry in its entirety is 
also 98% complete in terms of outcome ascertainment. This is made possible through national 
mortality and dialysis records, as well as continuous reporting between the 12 nephrology centers 
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coverage back to 1964, and is updated continuously with outcomes such as death and graft failure.[6, 
15]  
 Kaplan-Meier methods were used to estimate and display survival at each time period post 
transplant for the various eras of transplantation, which were categorised into 5 year brackets.  
Multivariable modeling on patient and graft survival outcomes were analysed using Cox Proportional 
Hazards methods stratified into successive time periods of 5 years with the proportional hazards 
assumption over time tested using Schoenfeld residuals.  
 The only component of this study which was directly not based on the NKTS Registry data 
were the half-life estimates which were solely based on data from the Collaborative Transplant Study 
(CTS) and provided by the CTS (see below). 
 Changes in maintenance immunosuppression regimes over time in the program are depicted 
in Figure 3. All kidney transplant recipients were ABO blood group compatible and had either 
negative complement dependent cytotoxicity (CDC), flow cross match or virtual cross match 
assays.[6] The program commenced using Flow cytometry routinely in 2004, with high-level 
screening and DP typing. A and B HLA loci were investigated pre transplant in the 1970s and 
extended to DR loci in the 1980s.[6]  
 Prior to 1986, all recipients were treated with Azathioprine and Prednisolone; thereafter all 
recipients received Ciclosporin (4mg/kg BD), Azathioprine (2mg/kg) and Prednisolone until the 
introduction of Tacrolimus, Mycophenolate and Prednisolone based regimes circa 2003 due to the 
summative supportive evidence internationally. [6, 16-22] (see Figure 3). Originally, acute rejections 
were treated with intravenous methylprednisolone and occasionally OKT3 was used in resistant 
cases.[6] Rabbit anti-thymocyte globulin (rATG) has been and still is used as induction therapy for 
recipients with high immunological risk characteristics and occasionally for steroid resistant acute 
rejection. Of the 3260 recipients included in this study, from 1971 to 2015, 71.5% received no 
induction immunosuppression, 2.18% rATG induction and 26.32% Basiliximab induction. In general 
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While the vast majority of study participants received their kidney transplant at Beaumont Hospital, 
the very first kidney transplant in Ireland was performed at St Vincent’s Hospital Dublin.  Delayed 
graft function is defined in this study as a requirement for dialysis in the first week following kidney 
transplant. STATA SE (version 13.1 StataCorp, Texas) was used for the data analysis and graphical 
presentation.  
 
Half-life estimates of graft and death-censored graft survival provided by CTS  
The estimated half-lives and respective 95% confidence intervals were calculated based on available 
survival information for patients with a minimum of 5-year observation time (if they did not lose their 
grafts earlier) assuming exponentially distributed survival times.[23] 3270 recipients from Ireland 
were included based on the following selection criteria: recipients of a first kidney-only deceased 
donor transplant from 1971-2015 and aged ≥ 18 years. Recipients from the most recent interval 
(2011-2015) were not included in the estimations since the 5-year observation-criterion was not 
fulfilled in all cases. These are univariate analysis, which do not consider other changing factors, such 
as the increasing donor age. [23]  
  
3. Results 
 Trends in donor and recipient characteristics are displayed in Table 1. Recipient median age 
(years) increased from 34.5 in 1971-1975 to 52.1 in 2011-2015 and donor median age (years) 
increased from 20 in 1971-1975 to 48 in 2011-2015, P for trend <0.001 for both comparisons (Table 
1). In terms of anti-HLA panel reactive antibodies (PRA), the proportion of patients in the mid to 
higher range of PRA increased over time, P for trend <0.001. The number of HLA mismatches also 
increased over time from 1.5 in 1976-1980 to 4 in 2011-2015, P for trend <0.001. Biopsy proven 
rejection within the first year (in biopsies performed for clinical indications) decreased over time, 










This article is protected by copyright. All rights reserved. 
trend <0.001 (Table 1). Trends in delayed graft function were biphasic with an initial decline and 
subsequent increase, P<0.001. Cold ischaemic time showed the opposite pattern, P<0.001, but 
remained low throughout the period.  Median time on dialysis prior to transplant (months) rose 
progressively over time in the program, from 12.8 months in 1971-1975 to 34.4 in 2011-2015, 
P<0.001 (Table 1). 
 Patient and uncensored graft survival, expressed as a percentage, is presented in Table 2. 
Uncensored graft and patient survival have improved over the course of the program at various time 
points (Figure 1A & 2A). For example at 10 years it has increased from 10% in 1971-1975 to 45% by 
1996-2000. (Table 2). At 30 years post transplant graft survival, expressed as a percentage, was 4% 
for allografts transplanted in 1971-1975, 9% for those in1976-1980 and 15% for those in 1981-1985 
(Table 2 and Figure 2A).  
 We then further explored early graft and patient survival to investigate whether the 
improvement in long-term graft function might be explained solely by improvements in early 
outcomes (Figure 1B & 2B). Life tables to accompany these Kaplan Meier curves are provided in 
supplementary Table 1. With regard to graft survival, the 2-year survival appeared to progressively 
improve, however the 5- and 10-year survival appear to have changed more markedly over 
consecutive eras of transplantation (Supplementary Table 1). A similar pattern was observed in 
recipient survival (Figure 1B & Supplementary Table 1). 
 
Half-lie estimates for graft and death-censored graft survival 
CTS half-life estimates indicate a progressive increase in allograft half-life to present (Table 4). 
Estimated graft half-lives increased from 6.7 years during 1971-1975 to 24.9 years during 2001-2005 
in the case of graft survival and from 13.4 years to as high as 42.7 years in the case of death-censored 
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4. Discussion  
 Long-term outcomes following deceased donor kidney transplantation have been 
progressively improving in Ireland. This contrasts with reports from many other kidney transplant 
programs internationally, particularly in the USA, which suggest a lack of improvement in long-term 
outcomes despite effective contemporary immunosuppression.[24, 25] These improvements in long-
term allograft outcomes have occurred despite an increased representation of features associated with 
graft failure over time such as increasing donor and recipient age, panel reactivity, HLA mismatches, 
and time on dialysis (Table 1). [26, 27] Although improvements in longer-term graft outcomes have 
also been reported elsewhere, particularly by other European programs and by ANZDATA, these 
reports tend to lack the duration of follow up we present in this study.[5, 6, 28-30]  
 A recent CTS study assessed trends in graft failure across 21 countries, and 135 transplant 
centers in Europe between 1986 and 2015. [31] This study found an improvement in the hazard of 
graft failure at 1, 5 and 10 years post transplant over this period. However the authors specify that 
while the improvements in the first 5 years post transplant have decreased since the year 2000, 
improvements after 5 years did not appear to plateau.[31] As a result, the improvements in long-term 
function were greater than short-term improvements from 2000-2015. [31] This study provides good 
evidence of generalized improvements across the European region as a whole gleaned from a larger 
diverse composite cohort. However, the inherent heterogeneity between different sites make the 
interpretation of these findings for individual programs more difficult to discern. This may be 
particularly true for comparisons to the early eras. It is also possible that data from larger EU 
countries are dominating the contribution to the overall estimates. Because the kidney transplant 
program in Ireland is based out of a single unit, perhaps this data may provide a more homogenous 
substrate for comparisons of outcomes over different time periods, particularly for comparisons to 
very early eras. In addition, with a single site forming the basis of the national kidney transplant 
program in Ireland it is perhaps easier to infer the possible impacts of changes to policy and practice 
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 Factors which associated with graft failure from multivariable models in the Irish program 
included older era of transplant, increasing donor age, donor sex and cold ischaemia time (Table 3). 
These findings were consistent with the larger CTS study across Europe.[31] Half-life estimations of 
graft survival performed by CTS, based on observed death-censored graft failure rates in Ireland, also 
indicated continued improvement in long-term graft survival (Table 4). 
 Improvements in early graft outcomes have been consistently reported across multiple 
territories, with comparable 1-year allograft survival rates between Europe and the USA, due to 
factors such as the reduction in hyperactive rejection resulting from improved immunological 
characterization.[5, 32] Intermediate outcomes are also improving, even in the USA, with a reduction 
in graft failure over the first 3 years despite increasingly deleterious risk factors for graft failure, 
coincident with the pervasive use of Tacrolimus and Mycophenolate based regimes.[3] However 
Lamb et al assessed changes in graft survival in the USA from 1989 to 2005, and found that, while 
attrition rates beyond the first year did show small improvements, the largest change was in first year 
attrition rates.[2] Improved long-term allograft survival may be partly attributable to these 
improvements in the early graft survival, but, as pointed out by Gaston, emerging data challenges the 
concept that early events are predominantly responsible for late graft failures.[33] Our analysis 
suggests that while there has been a progressive improvement in short-term outcomes (Figure 1B and 
2B), this does not appear to solely explain the long-term improvements.  
 These improvements in short-term outcomes over the past several decades in the USA, do not 
appear to have translated into comparable improvements in long term outcomes. [4] Deciphering the 
hierarchical importance of donor and recipient biologic and socioeconomic factors or medical 
treatment responsible for this discrepancy is difficult. Wang et al suggest that differences in case mix, 
allocation policy, and healthcare insurance coverage may partially explain this lack of improvement in 
long term function.[4] Recent reports also suggest that long term graft outcomes in Australia, New 
Zealand and the United Kingdom, exceed those of the USA, [34] and each country apart from the US 
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Europe suggest that while long term outcomes appear to be improving, the gains in short term 
outcomes may have plateaued.[31] 
 Undoubtedly the improvements in long term outcomes in Ireland compared to jurisdictions 
such as the US could potentially represent a selection bias, with a more racially, genetically and 
immunologically heterogeneous donor and recipient profile elsewhere. [3, 40, 41] However, the 
increased risk of adverse outcomes such as transplant rejection and graft loss known to associate with 
black race/ethnicity in the USA may not translate to other jurisdictions such as the United Kingdom, 
perhaps further evidence for the importance of non biological factors.[42]  
 Since the Irish kidney transplant program has almost 100% recipient follow up and National 
healthcare policy in Ireland removes some of the health inequalities associated with race and 
socioeconomic status seen in other programs, it provides an interesting substrate for assessing trends 
in allograft survival resulting from contemporary clinical management.[43, 44] In addition, although 
there is no direct evidence of superior medication compliance amongst Irish transplant recipients, 
failure to attend transplant clinic appointments is known to be relatively rare amongst recipients in 
Ireland. [6, 43, 45]  
 Evidence exists that socioeconomic factors such as access to medical care in other countries 
contributes to poorer outcomes following kidney transplant. [41, 46] As of 2013 Medicare coverage 
for most kidney transplant recipients in the US lasted only 3 years, which exposed transplant 
recipients to the expense of funding their immunosuppressive medications.[47] This report estimated 
that 40,000 recipients in the US were at risk for cost related non-adherence. [44]   
 Factors in addition to advances in immunosuppression protocols have likely contributed to 
improved long term outcomes such as; the developments in immunological assessments for donor 
specific antibodies and transplant glomerulopathy, the management of cardiovascular disease, cancer 
and opportunistic infections following transplantation, improved characterization of the BK virus and 
perhaps improvements in the treatment of primary diseases such as glomerulonephritis subtypes. [48, 
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improved graft outcomes.[50] Other possible explanations for the discrepancy in findings between 
Ireland and other programs include: the possibility of lower deceased donor quality elsewhere, or a 
lower rate of transplantation in Ireland overall in comparison to regions such as the US.  
With regard to patient survival, the gradual improvement in recipient survival seen in this 
study is commensurate with improvements seen in the general population and the dialysis population 
over a similar time frame. [51] These improvements in patient and graft survival have been mirrored 
by an improved survival in the general population, for instance, life expectancy has increased on 
average by 6.1 years for men and 4.9 years for women over the last 20 years in Ireland. [52] 
Improvements in graft survival in this setting is perhaps more impressive since a reduction in graft 
failure rates appears to have occurred despite an inflation in the population at risk.  An additional 
analysis assessing patient and graft survival from dialysis initiation may be of merit.  
Limitations of this study include its retrospective nature and since the projections for graft 
survival provided are speculative simulations; the lower failure rates in recent years may elevate the 
error around the models projections. In addition since the projections are based on observed trends in 
graft failure rates, they may assume a constant rate of improvement in graft survival rather than a 
plateau effect being reached at certain stages. However, it ought to be acknowledged that a number of 
the 95% confidence intervals for projected graft survival overlap (Table 4), and it is uncertain at this 
point internationally whether these long-term improvements will indeed plateau or continue. [31]  
 Whilst acknowledging systematic heterogeneity amongst the various kidney transplantation 
programs worldwide, and being cognizant of the need to continue to improve transplant care, [53] it is 
no longer true to suggest that long-term outcomes in kidney transplantation are failing to improve. 
The reasons for this improvement are unclear but likely represent a combination of biological and 
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Donor Age Donor Sex PRA HLA Mismatch 
Median [IQR]* % male (years) % male % 0-10/11-49/  Number (ABDR) 
   Median 
[IQR] 
50-84/ 85-100  Median [IQR] 
1971   to   1975 34.5  [24.2 - 42.4] 67.5 20 [17 - 47] 61.4 100/0/0/0  ---- 
1976   to   1980 39.1  [29.5 -46.6] 69 23 [18 - 38] 61.8 71/18/7/5 1.5 [1 - 2] 
1981   to   1985 37.3  [27.3 - 46.4] 69.2 24 [17 - 42] 63.6 65/18/10/7 2     [2 - 3] 
1986   to   1990 42.9  [31.3 - 54.8] 65 30 [19 - 42] 60.3 69/18/7/6 2     [1 - 3] 
1991   to   1995 45.1   [32.2 -56.0] 65.9 39 [21 - 51] 62.2 80/11/6/3 3     [2 - 3] 
1996   to   2000 45.0   [31.9 -55.4] 63.6 39 [22 - 47] 57.2 85/10/4/1 3     [2 - 4] 
2001   to   2005 47.9   [34.6- 58.2] 62.4 41 [25 - 50] 55.5 89/9/2/1 3     [2 - 4] 
2006   to   2010 50.0   [37.8- 60.1] 62 46 [31 - 55] 58 58/21/17/4 3     [3 - 5] 
2011   to   2015 52.1   [39.7 - 61.8] 63.5 48 [38 - 55] 58.6 32/34/26/8 4     [3 - 5] 
Trend  test  sign: Positive   Negative Positive  Negative Positive  Positive 
Trend test P value: <0.001 0.034 <0.001 0.098 <0.001 <0.001 
Era 
Deceased donor subtype 
Biopsy 
Rejection 
Delayed Cold Ischaemia  Time on dialysis 
CAD (%) DCD (%) In year 1 (%) 
Graft  
Function (%) 
Time (hours)  (months) 
    Median[IQR] Median[IQR] 
1971   to   1975 100 0 16.9 73.9 10 [7 - 12] 12.8 [6.55 - 21.1] 
1976   to   1980 100 0 41.9 47.3 10 [8 - 12] 14.5 [7.85 - 33.4] 
1981   to   1985 100 0 65.6 30.7 19 [15 - 22] 16.8 [9.79 - 33.5] 
1986   to   1990 100 0 35.8 14.2 21 [19 - 24] 20.2 [8.97 - 34.1] 
1991   to   1995 100 0 19.5 10 22 [19 - 25] 16.5 [9.86 - 27.6] 
1996   to   2000 100 0 26.1 7.4 21 [18 - 25] 16.1 [9.92 - 24.9] 
2001   to   2005 100 0 16 16.8 19 [17 - 22] 20.9 [13.5 - 32.7] 
2006   to   2010 100 0 12.2 16.2 16 [13 - 18] 31.3 [19.2 - 44.5] 
2011   to   2015 94.16 5.84 11.5 17.5 14 [12 - 17] 34.4 [18.8 – 51.0] 
Trend  test  sign:  -  - Negative Negative Negative Positive 
Trend test P value:  -  - <0.001 <0.001 <0.001 <0.001 
 
*Either median and interquartile range [IQR] or percentages are used to compare eras. PRA; panel reactive 
antibody, HLA; human leucocyte antigen. Biopsy rejection in the 1st year refers to biopsies done for clinical 
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Table 2. Patient and uncensored allograft survival (expressed as a percentage) post kidney transplantation 





Number Year post transplant 
of recipients % Survival 
  1 5 10 15 20 25 30 35 40 
  % % % % % % % % % 
2011 - 2015 548 98                 
2006 - 2010 524 99 91               
2001 - 2005 481 96 90 79             
1996 - 2000 456 96 87 79 68           
1991 - 1995 481 94 83 68 54 44         
1986 - 1990 369 94 83 67 51 39 30       
1981 - 1985 195 90 78 69 53 44 38 30     
1976 - 1980 129 73 59 50 40 31 21 19 12   
1971 - 1975 77 51 39 31 24 17 16 15 13 11 
Allograft Survival (uncensored) 
Era 
transplanted 
Number Year post transplant 
of recipients % Survival 
  1 5 10 15 20 25 30 35 40 
  % % % % % % % % % 
2011 - 2015 548 97                 
2006 - 2010 524 96 88               
2001 - 2005 481 93 83 67             
1996 - 2000 456 88 74 58 45           
1991 - 1995 481 86 69 48 34 26         
1986 - 1990 369 86 66 44 28 19 13       
1981 - 1985 195 68 55 44 33 26 21 15     
1976 - 1980 129 59 46 35 27 19 11 9 7   
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Recipient survival Graft survival (uncensored) 
AHR 95% CI P value AHR 95% CI P value 
Era* 
 
0.790 0.749,   0.833 <0.001 0.730 0.701,  0.760 <0.001 
Recipient   age 
Reference  age    45 –   54  
                   age   18 –   34 
                    age   35  -  44 
                    age   55 –  64  









0.115,  0.193 
0.358,  0.569 
1.399,  2.063 















0.709,  0.996 
0.669,  0.974 
0.819,  1,169 







Male sex  1.191 1.022,  1.388 0.025 0.949 0.839,  1.074 0.406 
Donor age  
Reference age    19 – 29 
                   age    < 18   
                   age    30  - 39    
                   age    40  - 49    
                   age    50  - 59    










0.831,  1.393 
0.810,  1.383 
0.922,  1.464 
0.896,  1.437 

















0.927,  1.389 
0.783,  1.195 
0.954,  1.375 
1.023,  1.498 








Donor sex  0.993 0.859,  1.149 0.930 0.853 0.755,  0.962 0.010 
PRA group  0.932 0.848,  1.024 0.141 0.988 0.910,  1.073 0.776 
Number HLA mismatch 1.023 0.965,  1.085 0.444 1.033 0.986,  1.083 0.173 
Cold Ischaemic Time 1.012 0.999,  1.024 0.072 1.017 1.007,  1.028 0.001 
Time on dialysis  1.003 1.001,  1.005 0.002 1.001 0.998,  1.004 0.452 
 
 
*Eras in 10 year periods commencing in 1971 except the last era which was 5 year period 2011-2015. AHR; 
adjusted hazard ratio, CI; confidence interval, P; P value. The unit of measure for each variable of interest above 
included: cold ischemic time in hours, and time on dialysis in months. PRA was grouped into the following 
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Table 4. Half-life estimates and corresponding 95% confidence intervals (CI) of graft and death-censored graft 
survival of adult first deceased donor kidney-only transplants. 
 
Transplant Years Patients 
Graft Survival Death-Censored Graft Survival 
Half Life 95% CI Half Life 95% CI 
1971 – 1975 80 6.7 3.6   – 12.5 13.4 5.6  – 32.3 
1976 – 1980 127 11.0 6.8   – 17.7 13.4 7.9  – 22.6 
1981 – 1985 194 12.5 8.5   – 18.4 19.1 11.9 – 30.7 
1986 – 1990 369 10.7 8.5   – 13.5 18.6 13.8 – 25.2 
1991 – 1995 481 12.9 10.3 – 16.0 21.3 16.1 – 28.1 
1996 – 2000 460 15.3 12.0 – 19.5 26.6 19.4 – 36.5 
2001 – 2005** 486 24.9 18.8 – 33.0 42.7 29.5 – 61.8 
 






Figure 1. A Patient (recipient) survival over the course of the National Kidney Transplant Service Program in 
Ireland stratified by era of transplant (N=3260). B Patient survival by era of transplantation conditional on 
survival in the first year following kidney transplant (N=3260). 
 
Figure 2. A Graft survival (uncensored) over the course of the National Kidney Transplant Program in Ireland 
stratified by era of transplant (N=3260). B Graft survival by era of transplantation conditional on survival in the 
first year following kidney transplant (N=3260). 
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Figure 1. A Patient (recipient) survival over the course of the National Kidney Transplant Service Program in 
Ireland stratified by era of transplant (N=3260). B Patient survival by era of transplantation conditional on 
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Figure 2. A Graft survival (uncensored) over the course of the National Kidney Transplant Program in Ireland 
stratified by era of transplant (N=3260). B Graft survival by era of transplantation conditional on survival in the 
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Trends in Induction agents for kidney transplant as a percentage of the total for each period:  
• ATG; 0% from 1971-1985, 0.81% 1986-1990, 4.16% 1991-1995, 3.73% 1996-2000, 1.04% 2001-2005, 0.76% in 2006-2010, 
4.01% in 2011-2015. 
• Basiliximab: 1971-2000 0%, 2001-2005 0.21%, 2006-2010 77.1%, 2011-2015 82.66%. 
• No Induction: 1971-1985 100%, 1986-1990 99.19%, 1991-1995 95.84%, 1996-2000 96.27%, 2001-2005 98.75%, 2006-2010 
22.14%, 2011-2015 13.32%. 
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